- Home
- ELS vs INCY Comparison
ELS vs INCY Comparison
Compare ELS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELS
- INCY
- Stock Information
- Founded
- ELS 1992
- INCY 1991
- Country
- ELS United States
- INCY United States
- Employees
- ELS N/A
- INCY N/A
- Industry
- ELS Real Estate Investment Trusts
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ELS Real Estate
- INCY Health Care
- Exchange
- ELS Nasdaq
- INCY Nasdaq
- Market Cap
- ELS 11.7B
- INCY 13.0B
- IPO Year
- ELS 1993
- INCY 1993
- Fundamental
- Price
- ELS $60.17
- INCY $78.39
- Analyst Decision
- ELS Buy
- INCY Buy
- Analyst Count
- ELS 11
- INCY 20
- Target Price
- ELS $71.50
- INCY $79.06
- AVG Volume (30 Days)
- ELS 2.0M
- INCY 1.7M
- Earning Date
- ELS 07-21-2025
- INCY 07-29-2025
- Dividend Yield
- ELS 3.42%
- INCY N/A
- EPS Growth
- ELS 1.09
- INCY 900.04
- EPS
- ELS 1.94
- INCY 4.37
- Revenue
- ELS $1,534,019,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- ELS $1.67
- INCY $13.53
- Revenue Next Year
- ELS $4.24
- INCY $10.38
- P/E Ratio
- ELS $31.06
- INCY $17.94
- Revenue Growth
- ELS 1.05
- INCY 18.87
- 52 Week Low
- ELS $58.15
- INCY $53.56
- 52 Week High
- ELS $76.60
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ELS 44.88
- INCY 68.30
- Support Level
- ELS $58.15
- INCY $76.45
- Resistance Level
- ELS $62.50
- INCY $79.43
- Average True Range (ATR)
- ELS 1.45
- INCY 2.16
- MACD
- ELS 0.15
- INCY 0.54
- Stochastic Oscillator
- ELS 46.44
- INCY 91.50
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.